Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.

Terumo BCT’s Spectra Optia^® Apheresis System, an FDA-cleared and CE marked device for use in therapeutic apheresis and cell collection procedures, will be incorporated into CANCER-ID research efforts that will evaluate diagnostic leukapheresis (DLA) as a means to capture and harvest larger numbers of CTCs.* This research may uncover a diagnostic application for the Spectra Optia system, which is currently used in hospitals and blood centers around the world.

Terumo BCT is pleased to partner with CANCER-ID, furthering the consortium’s mission of developing standards and conducting clinical validation to enable broad adoption of reliable molecular analyses from liquid biopsies.